更新版诊断特异性分级预后评估与入组资格商定义:脑转移患者生存总结报告
基于多机构6984例新诊断脑转移患者数据库,按原发部位进行多变量分析确定预后因素并更新GPA。更新版GPA各亚组间生存分离稳健(P<.01),不同原发肿瘤GPA对应中位生存差异大。建议以GPA分层临床试验,并推荐将既往治疗过脑转移且额外一年生存概率≥50%(资格商>0.50)的患者纳入入组范围。
要点
- 更新版GPA按原发部位纳入新预后因素,亚组间生存分离稳健(P<.01)。
- 不同原发肿瘤脑转移患者中位生存随GPA变化范围大,如NSCLC为7-47个月。
- 建议临床试验按GPA分层,并扩大入组至资格商>0.50的既往治疗脑转移患者。
核心结论
- 脑转移患者中位生存差异大,更新版GPA可更准确估计生存、个体化治疗并分层临床试验。
- 不应排除脑转移患者入组临床试验,而应按GPA分层以确保恰当比较。
- 推荐扩大入组资格,允许既往治疗过脑转移且额外一年生存概率≥50%(资格商>0.50)的患者入组。
研究设计与样本
- 多机构数据库纳入6984例新诊断脑转移患者。
- 按原发部位进行多变量分析,识别与生存相关的预后因素和治疗。
- 将显著因素纳入更新版GPA,GPA 4.0与0.0分别对应最佳与最差预后。
主要发现
- 显著预后因素因诊断而异,并识别出新的预后因素。
- 更新版GPA各亚组间生存分离稳健(P<.01)。
- 中位生存随GPA变化范围:非小细胞肺癌7-47个月,乳腺癌3-36个月,黑色素瘤5-34个月,胃肠道肿瘤3-17个月,肾癌4-35个月。
关键数值与推荐
- GPA 4.0对应最佳预后,GPA 0.0对应最差预后。
- 更新版GPA各亚组间生存分离P<.01。
- 资格商>0.50定义为额外一年生存概率≥50%。
临床怎么用
- 使用更新版GPA(brainmetgpa.com免费获取)估计脑转移患者生存并个体化治疗。
- 临床试验应按GPA分层,而非排除脑转移患者。
- 可考虑纳入既往治疗过脑转移且资格商>0.50的患者进入临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Conventional wisdom has rendered patients with brain metastases ineligible for clinical trials for fear that poor survival could mask the benefit of otherwise promising treatments. Our group previously published the diagnosis-specific Graded Prognostic Assessment (GPA). Updates with larger contemporary cohorts using molecular markers and newly identified prognostic factors have been published. The purposes of this work are to present all the updated indices in a single report to guide treatment choice, stratify research, and define an eligibility quotient to expand eligibility. METHODS: A multi-institutional database of 6,984 patients with newly diagnosed brain metastases underwent multivariable analyses of prognostic factors and treatments associated with survival for each primary site. Significant factors were used to define the updated GPA. GPAs of 4.0 and 0.0 correlate with the best and worst prognoses, respectively. RESULTS: Significant prognostic factors varied by diagnosis and new prognostic factors were identified. Those factors were incorporated into the updated GPA with robust separation (P < .01) between subgroups. Survival has improved, but varies widely by GPA for patients with non-small-cell lung, breast, melanoma, GI, and renal cancer with brain metastases from 7-47 months, 3-36 months, 5-34 months, 3-17 months, and 4-35 months, respectively. CONCLUSION: Median survival varies widely and our ability to estimate survival for patients with brain metastases has improved. The updated GPA (available free at brainmetgpa.com) provides an accurate tool with which to estimate survival, individualize treatment, and stratify clinical trials. Instead of excluding patients with brain metastases, enrollment should be encouraged and those trials should be stratified by the GPA to ensure those trials make appropriate comparisons. Furthermore, we recommend the expansion of eligibility to allow for the enrollment of patients with previously treated brain metastases who have a 50% or greater probability of an additional year of survival (eligibility quotient > 0.50).
引用
- Sperduto PW, Mesko S, Li J, et al. Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. J Clin Oncol. 2020. PMID: 32931399. doi:10.1200/JCO.20.01255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。